Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Non-Current Deffered Revenue (2021 - 2025)

Ascendis Pharma A (ASND) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue fell 75.53% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 75.53% year-over-year, with the annual reading at $1.3 million for FY2025, 75.53% down from the prior year.
  • Non-Current Deffered Revenue hit $1.3 million in Q4 2025 for Ascendis Pharma A, down from $5.3 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $14.5 million in Q4 2022 to a low of $1.3 million in Q4 2025.
  • Historically, Non-Current Deffered Revenue has averaged $6.2 million across 5 years, with a median of $5.3 million in 2024.
  • Biggest five-year swings in Non-Current Deffered Revenue: soared 327.66% in 2022 and later plummeted 75.53% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $3.4 million in 2021, then surged by 327.66% to $14.5 million in 2022, then plummeted by 55.86% to $6.4 million in 2023, then decreased by 16.53% to $5.3 million in 2024, then tumbled by 75.53% to $1.3 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for ASND at $1.3 million in Q4 2025, $5.3 million in Q4 2024, and $6.4 million in Q4 2023.